Eisenmenger Syndrome Treatment Market
Eisenmenger Syndrome Treatment Market Size, Share & Trends Analysis Report by Drug Type (Antiarrhythmic Agents, Blood Thinning Agents, Endothelin Receptor Antagonist, and Others) by Diagnosis (Blood Tests, Electrocardiogram (ECG), Chest X-Ray, Echocardiogram, Computerized Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), and Cardiac Catheterization) and by Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies) Forecast Period (2022-2028) Update Available - Forecast 2024-2030
Eisenmenger syndrome treatment market is anticipated to grow at a CAGR during the forecast period. The primary factor that drives the market growth is the increasing number of cardiovascular patients, and high blood pressure cases globally, along with the rising R&D practices in the pharmaceutical field for treating Eisenmenger syndrome by public and private sectors, are projected to drive the market growth during the forecast period. For instance, in June 2020, Bayer announced the launch of the second annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards to support clinical research in pulmonary hypertension (PH), with a focus on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The program has awarded up to a total of $1 million in grants, the research project duration can extend over two years, and Bayer has invited applications for US based clinical research in PAH or CTEPH. The Eisenmenger syndrome is an advanced form of pulmonary artery hypertension and develops over time, due to high blood pressure in the lungs related to certain heart defects present at birth. Moreover, the expansion also has been driven by the immense availability of disease-targeting treatment such as Sildenafil, and Bosentan has increased the market growth.
Segmental Outlook
The global eisenmenger syndrome treatment market is segmented based on drug type, diagnosis, and distribution channel. Based on drug type, the market is bifurcated into antiarrhythmic agents, blood thinning agents, endothelin receptor antagonist, and others. Based on diagnosis the market is sub-segmented into blood tests, electrocardiogram (ECG), chest x-ray, echocardiogram, computerized tomography (CT) scan, magnetic resonance imaging (MRI), and cardiac catheterization. Based on distribution channel the market is sub-divided into hospital pharmacies, online pharmacies, and retail pharmacies. Based on drug type, the endothelin receptor antagonist segment is expected to grow at a significant rate, it is widely used to treat people with pulmonary hypertension (PH). The prominent factor that boosts the segment growth is the rising frequency of cardiovascular diseases, along with the rising senior population, which is more prone to idiopathic pulmonary arterial hypertension (IPAH), which is fueling the segment expansion during the forecast period.
Regional Outlooks
The global eisenmenger syndrome treatment market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The Asia-Pacific region is expected to hold considerable growth during the forecast period. The growth is mainly driven owing to increasing expenditure on R&D , key companies, and government initiatives to spread information regarding Eisenmenger syndrome among healthcare professionals and patients, which is expected to boost the market growth in the region. As per the Statistics Bureau of Japan, Japan's total expenditure on R&D in 2019 stood at $ 146.56 trillion, a 0.3% increase from the previous year, and it has increased for three consecutive years.
Global Eisenmenger Syndrome Treatment Market Growth, by Region 2022-2028
The North American witness a Favourable Growth in the Global Eisenmenger Syndrome Treatment Market
The North American region is expected to dominate the market growth. The primary factor that contributes to the market growth is the rising number of cardiovascular patients, rapidly increasing cases of pulmonary hypertension, along with rising cases of COVID-19 pandemic leads to a rise in the demand for the market in the region. For instance, according to the American College of Cardiology, in a US survey of 77 Comprehensive Care Centers for pulmonary hypertension (PH), the incidence of COVID-19 infection in patients with pulmonary arterial hypertension (PAH) was 2.1 cases per 1,000 patients, and associated mortality was 12%.
Market Players Outlook
The major companies serving the global eisenmenger syndrome treatment market include AstraZeneca, Bayer AG, Johnson & Johnson Pte. Ltd Pharmaceuticals Corp., Pfizer Inc., GlaxoSmithKline ,Hikma Pharmaceuticals PLC, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in May 2022, Zydus Lifesciences announce that its subsidiary, Zydus Worldwide DMCC secured a tentative approval from the US-based drug regulatory body, US Food and Drug Administration (USFDA) to market Selexipag tablets. Selexipag is used in adults to treat pulmonary arterial hypertension (PAH) to delay disease progression and reduce the risk of hospitalization for PAH.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global eisenmenger syndrome treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Recovery Scenario of Global Eisenmenger Syndrome Treatment Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. AstraZeneca
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Bayer AG
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Johnson & Johnson Pte. Ltd
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. Novartis Pharmaceuticals Corp.
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.1.5. Pfizer Inc.
3.1.5.1. Overview
3.1.5.2. Financial Analysis
3.1.5.3. SWOT Analysis
3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Segmentation
4.1. Global Eisenmenger Syndrome Treatment Market by Drug Type
4.1.1. Antiarrhythmic Agents
4.1.2. Blood Thinning Agents
4.1.3. Endothelin Receptor Antagonist
4.1.4. Others
4.2. Global Eisenmenger Syndrome Treatment Market by Diagnosis
4.2.1. Blood tests
4.2.2. Electrocardiogram (ECG)
4.2.3. Chest X-ray
4.2.4. Echocardiogram
4.2.5. Computerized tomography (CT) scan
4.2.6. Magnetic resonance imaging (MRI)
4.2.7. Cardiac catheterization
4.3. Global Eisenmenger Syndrome Treatment Market by Distribution Channel
4.3.1. Hospital Pharmacies
4.3.2. Online Pharmacies
4.3.3. Retail Pharmacies
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Eli Lilly and Co.
6.2. Gilead Sciences, Inc.
6.3. GlaxoSmithKline
6.4. Hikma Pharmaceuticals PLC
6.5. Lupin Ltd.
6.6. Merck & Co., Inc.
6.7. Natco Pharma Ltd.
6.8. Sun Pharma
6.9. Viatris Inc
6.10. Zydus Pharmaceuticals (USA) Inc.
1. GLOBAL EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
2. GLOBAL ANTIARRHYTHMIC AGENTS IN EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL BLOOD THINNING AGENTS IN EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL ENDOTHELIN RECEPTOR ANTAGONIST IN EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL OTHER DRUG IN EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
7. GLOBAL BLOOD TEST FOR EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL ELECTROCARDIOGRAM (ECG) FOR EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL CHEST X-RAY FOR EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL ECHOCARDIOGRAM FOR EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL COMPUTERIZED TOMOGRAPHY (CT) SCAN FOR EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) FOR EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13. GLOBAL CARDIAC CATHERIZATION FOR EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14. GLOBAL EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
15. GLOBAL HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
16. GLOBAL ONLINE PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
17. GLOBAL RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
18. GLOBAL EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
19. NORTH AMERICAN EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. NORTH AMERICAN EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
21. NORTH AMERICAN EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
22. NORTH AMERICAN EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
23. EUROPEAN EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
24. EUROPEAN EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
25. EUROPEAN EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
26. EUROPEAN EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
27. ASIA-PACIFIC EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
28. ASIA-PACIFIC EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
29. ASIA-PACIFIC EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
30. ASIA-PACIFIC EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
31. REST OF THE WORLD EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
32. REST OF THE WORLD EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
33. REST OF THE WORLD EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
34. REST OF THE WORLD EISENMENGER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
1. GLOBAL EISENMENGER SYNDROME TREATMENT MARKET SHARE BY DRUG TYPE, 2021 VS 2028 (%)
2. GLOBAL ANTIARRHYTHMIC AGENTS IN EISENMENGER SYNDROME TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
3. GLOBAL BLOOD THINNING AGENTS IN EISENMENGER SYNDROME TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
4. GLOBAL ENDOTHELIN RECEPTOR ANTAGONIST IN EISENMENGER SYNDROME TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
5. GLOBAL OTHER DRUGS IN EISENMENGER SYNDROME TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL EISENMENGER SYNDROME TREATMENT MARKET SHARE BY DIAGNOSIS, 2021 VS 2028 (%)
7. GLOBAL BLOOD TEST FOR EISENMENGER SYNDROME TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL ELECTROCARDIOGRAM (ECG) FOR EISENMENGER SYNDROME TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL CHEST X-RAY FOR EISENMENGER SYNDROME TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL ECHOCARDIOGRAM FOR EISENMENGER SYNDROME TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL COMPUTERIZED TOMOGRAPHY (CT) SCAN FOR EISENMENGER SYNDROME TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) FOR EISENMENGER SYNDROME TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL CARDIAC CATHERIZATION FOR EISENMENGER SYNDROME TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL EISENMENGER SYNDROME TREATMENT MARKET SHARE BY DISTRIBUTION CHANNEL, 2021 VS 2028 (%)
15. GLOBAL HOSPITAL PHARMACIES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16. GLOBAL ONLINE PHARMACIES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
17. GLOBAL RETAIL PHARMACIES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
18. GLOBAL EISENMENGER SYNDROME TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
19. US EISENMENGER SYNDROME TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
20. CANADA EISENMENGER SYNDROME TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
21. UK EISENMENGER SYNDROME TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
22. FRANCE EISENMENGER SYNDROME TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
23. GERMANY EISENMENGER SYNDROME TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
24. ITALY EISENMENGER SYNDROME TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
25. SPAIN EISENMENGER SYNDROME TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
26. REST OF EUROPE EISENMENGER SYNDROME TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
27. INDIA EISENMENGER SYNDROME TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
28. CHINA EISENMENGER SYNDROME TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
29. JAPAN EISENMENGER SYNDROME TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
30. SOUTH KOREA EISENMENGER SYNDROME TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
31. REST OF ASIA-PACIFIC EISENMENGER SYNDROME TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
32. REST OF THE WORLD EISENMENGER SYNDROME TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
